Introduction {#s1}
============

Septins are a conserved group of GTP-binding proteins that play a crucial role in cytokinesis, cytoskeleton, and cell cycle control ([@B11]; [@B24]). As a star member of the *Septin* gene family, *Septin 9 (SEPT9)* is located at chromosome 17q25.3 and demonstrates both oncogenic and tumor-suppressive impacts on human cancers ([@B6]; [@B30]). Previous studies have uncovered that methylated *SEPT9* (*mSEPT9*) is associated with tumorigenesis based on transcriptionally silencing due to aberrant hypermethylation of the CpG island within the *SEPT9* promoter ([@B6]; [@B33]; [@B32]). Detection of *mSEPT9* has been reported in several cancers, including colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and gastric cancer (GC) ([@B18]; [@B25]; [@B26]).

Nowadays, the diagnostic significance of *mSEPT9* has been elucidated in several cancers, and specially, the *mSEPT9* assay (Epi proColon) becomes the first blood-based test approved by U.S. FDA for CRC screening. Some researches further pay attention to the *mSEPT9*'s prognostic performance on cancer. In 2013, Dietrich et al. detected malignant pleural effusions from 58 cases with various cancers and found that *mSEPT9* indicated a poor survival ([@B8]). Subsequently, the association of *mSEPT9* with cancer prognosis was investigated in CRC ([@B18]; [@B28]; [@B10]; [@B26]), GC ([@B18]), HNSCC ([@B25]), and so on ([@B17]; [@B1]; [@B3]; [@B15]).

To date, however, the prognostic value of *mSEPT9* in cancer patients has not yet been methodically elucidated. Herein, we performed a systematic review and meta-analysis to summarize the published data and evaluate the prognostic impact of *mSEPT9* on human cancers.

Materials and Methods {#s2}
=====================

Our meta-analysis was conducted based on the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ([@B19]). The PRISMA 2009 checklist is shown in [**Supplementary Table S1**](#SM3){ref-type="supplementary-material"}.

Search Strategy {#s2_1}
---------------

A comprehensive electronic search was performed *via* the EMBASE, PubMed, and ISI Web of Science databases through January 2019 without any restriction. The search items were combinations of "SEPT9," "mSEPT9," "septin 9," "prognosis" and "survival." There was no language restriction.

Criteria of Inclusion and Exclusion {#s2_2}
-----------------------------------

Two independent authors conducted the literature search and study selection. Discrepancies were resolved by discussion. Studies were considered eligible if they met the following criteria: (1) cohort studies for evaluating the prognostic role of *mSEPT9* in cancer patients; and (2) studies reporting hazard ratios (HRs) and 95% confidence intervals (CIs) or providing information to estimate HRs. The exclusion criteria were as follows: (1) reviews, meta-analyses, opinion, abstracts, and cellular or animal experiments; and (2) studies with overlapping data. If studies had overlapping data, we kept the one with the larger sample size.

Data Extraction {#s2_3}
---------------

Two independent authors extracted the following items from each included study: first author, publication year, country, patient number, sampling time, follow-up, cancer type and stage, detection method, and prognostic outcomes. Outcome measures included overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and progression-free survival (PFS).

Quality Evaluation {#s2_4}
------------------

Two authors independently conducted quality evaluation, and discrepancies were resolved by discussion. We used the Newcastle-Ottawa scale (NOS) to assess the quality of each included study, with quality score from 0 to 9 ([**Supplemental Table S2**](#SM4){ref-type="supplementary-material"}) ([@B27]). Quality evaluation was not an exclusion criterion for eligible studies.

Statistical Analysis {#s2_5}
--------------------

Multivariate-adjusted HRs and 95% CIs were preferentially extracted from each included study, if available. If a study did not report the HR and 95% CI, these measures were extrapolated by the method of Parmar and Tierney ([@B22]; [@B29]). We used the random-effects model (DerSimonian and Laird) to pool these HRs and 95% CIs and examined the heterogeneity by Cochran's Q test and *I^2^* statistic ([@B14]; [@B12]). *P* \< 0.10 or *I^2^* \> 50% indicates considerable heterogeneity ([@B13]). We also performed subgroup analyses to further evaluate the *mSEPT9*'s prognostic effects based on sample type, sampling time, and cancer type. To assess the stability of pooled results, we applied one-way sensitivity analysis by excluding one study at a time. In addition, the publication bias was examined by Begg's and Egger's tests ([@B2]; [@B9]). All *P* values were two-sided, and *P* ≤ 0.05 was considered significant, unless otherwise specified. All statistical analyses were carried out by Stata 12.1 software (College Station, TX, USA).

Results {#s3}
=======

Study Characteristics {#s3_1}
---------------------

Our search strategy initially obtained 275 records from the PubMed, EMBASE. and Web of Science databases. By title and abstract review, we removed 114 duplicates and 146 records. This large proportion of excluded records consisted of reviews, opinions, conference abstracts, diagnostic studies, *in vitro* studies, and nonhuman studies. Of the remaining 15 full-text publications, five studies were further excluded because of focusing on lymph node metastasis ([@B20]), having overlapping data ([@B7]), or insufficient information to estimate HRs and 95% CIs ([@B23]; [@B31]; [@B4]). Finally, a total of 10 eligible studies were included for this meta-analysis ([@B8]; [@B18]; [@B17]; [@B28]; [@B1]; [@B3]; [@B15]; [@B25]; [@B10]; [@B26]) ([**Figure 1**](#f1){ref-type="fig"}).

![A flowchart of literature search and study selection.](fgene-10-00887-g001){#f1}

Among these studies including 1,266 cancer patients, seven evaluated the *mSEPT9*'s prognostic significance on OS ([@B8]; [@B17]; [@B28]; [@B3]; [@B15]; [@B25]; [@B26]), two evaluated DFS ([@B18]; [@B28]), two evaluated DSS ([@B1]; [@B10]), and two evaluated on PFS ([@B1]; [@B25]). There were four studies using plasma or serum, of which three collected preoperative samples ([@B18]; [@B25]; [@B26]) and one collected postoperative samples ([@B28]). Other studies used tissues ([@B1]; [@B3]; [@B10]), ascites ([@B15]), or pleural effusions ([@B8]). The cancer type comprised CRC ([@B18]; [@B28]; [@B10]; [@B26]), GC ([@B18]), HNSCC ([@B25]), biliary tract carcinoma (BTC) ([@B3]), prostate cancer (PC) ([@B1]), esophageal squamous cell carcinoma (ESCC) ([@B17]), and multiple cancers (MC) ([@B8]; [@B15]). The quality of these studies were assessed by NOS score. More details about characteristics of included studies and cancer patients are summarized in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}.

###### 

Characteristics of studies included in this meta-analysis.

  Study                        Country       Patient number   Sample type         Sampling time   Follow-up                                                         Cancer type   Cancer stage   Detection method                                Outcomes   NOS score   HR estimation
  ---------------------------- ------------- ---------------- ------------------- --------------- ----------------------------------------------------------------- ------------- -------------- ----------------------------------------------- ---------- ----------- ---------------
  [@B26]                       China         99               Plasma              Preoperative    NA                                                                CRC           I--III         Epi proColon 2.0                                OS         4           Reported
  [@B10]                       Portugal      214              Tissues             Postoperative   NA                                                                CRC           I--IV          qPCR                                            DSS        7           Reported
  [@B25] (Training cohort)     Germany       129              Plasma              Preoperative    NA                                                                HNSCC         I--IV          qPCR                                            OS; PFS    6           Reported
  [@B25] (Validation cohort)   Germany       137              Plasma              Preoperative    NA                                                                HNSCC         I--IV          qPCR                                            OS         6           Reported
  [@B15]                       Germany       81               Ascites             NA              Mean (Range): 141 d (0--832 d); Median (Range): 56 d (0--832 d)   MC            I--IV          qPCR                                            OS         5           Extrapolated
  [@B3]                        Germany       71               Tissues             Postoperative   Mean (Range): 23 m (0--104m); Median (Range): 15 m (0--104m)      BTC           I--IV          qPCR                                            OS         5           Reported
  [@B1]                        Spain         45               Tissues             Postoperative   NA                                                                PC            I--IV          Golden Gate Methylation Cancer Panel I          DSS; PFS   8           Reported
  [@B28]                       Singapore     150              Serum               Postoperative   Median (Range): 59 m (5--79 m)                                    CRC           I--III         qPCR                                            OS; DFS    8           Reported
  [@B17]                       China         61               Tissues             Postoperative   Mean (Range): 19.6m (1.5--68.0 m)                                 ESCC          I-IV           Pyrosequencing quantitative methylation assay   OS         5           Extrapolated
  [@B18]                       South Korea   138              Plasma              Preoperative    Mean (Range): 413 d (397---460 d)                                 GC            I-IV           qPCR                                            DFS        5           Extrapolated
  [@B18]                       South Korea   83               Plasma              Preoperative    Mean (Range): 518 d (492---543 d)                                 CRC           I-IV           qPCR                                            DFS        5           Extrapolated
  [@B8]                        Germany       58               Pleural effusions   NA              Mean (Range): 62 d (0--250 d)                                     MC            NA             qPCR                                            OS         5           Extrapolated

CRC, colorectal cancer; HNSCC, head and neck squamous cell carcinoma; MC, multiple cancers; BTC, biliary tract carcinoma; PC, prostate cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; qPCR, quantitative real-time polymerase chain reaction; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival; DFS, disease-free survival; NOS, Newcastle-Ottawa Scale; d, days; m, months; NA, not available; HR, hazard ratio.

###### 

Characteristics of included patients based on cancer type.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer type   Number of included patients   Number of included studies   Age (years)                                                                          Male, n (%)   Stage                                                      *mSEPT9*-positive   Sample type                  Sampling time
  ------------- ----------------------------- ---------------------------- ------------------------------------------------------------------------------------ ------------- ---------------------------------------------------------- ------------------- ---------------------------- -----------------------------
  CRC           546                           4                            [@B26]: \< 40: n = 4; 40--49: n = 11; 50--59: n = 17; 60--69: n = 46; ≥70: n = 21\   336 (61.5)    [^a^](#fnT2_1){ref-type="table-wrap-foot"}TNM I--IV:\      NA                  Plasma, serum, tissues       Preoperative, Postoperative
                                                                           [@B10]: mean (range): 60.35 (25--80)\                                                              I/II: n = 250;\                                                                                             
                                                                           [@B28]: median (range): 67 (33--88)\                                                               III: n = 187;\                                                                                              
                                                                           [@B18]: mean (SD): 63.59 (11.14)                                                                   IV: n = 125                                                                                                 

  MC            139                           2                            NA                                                                                   NA            TNM I--IV, patient number of each stage was not provided   31/139 (22%)        Ascites, pleural effusions   NA

  HNSCC         266                           1                            NA                                                                                   NA            I--IV, patient number of each stage was not provided       NA                  Plasma                       Preoperative

  BTC           71                            1                            median (range): 63 (36--83)                                                          42 (59)       UICC I: n = 4;\                                            16/71 (23%)         Tissues                      Postoperative
                                                                                                                                                                              UICC II: n = 9;\                                                                                            
                                                                                                                                                                              UICC III: n = 28;\                                                                                          
                                                                                                                                                                              UICC IV: n = 10;\                                                                                           
                                                                                                                                                                              Unknown: n = 20.                                                                                            

  PC            45                            1                            mean (SD): 68.7 (7.7)                                                                45 (100)      TNM I--IV, patient number of each stage was not provided   NA                  Tissues                      Postoperative

  GC            138                           1                            NA                                                                                   NA            TNM I--IV, patient number of each stage was not provided   20/138 (14%)        Plasma                       Preoperative

  ESCC          61                            1                            \<65: n = 43; \>65: n = 18                                                           NA            TNM I--IV,\                                                22/61 (36%).        Tissues                      Postoperative
                                                                                                                                                                              Early (I/II): n = 15;\                                                                                      
                                                                                                                                                                              Late (III/IV): n = 46                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRC, colorectal cancer; MC, multiple cancers; HNSCC, head and neck squamous cell carcinoma; BTC, biliary tract carcinoma; PC, prostate cancer; GC, gastric cancer; ESCC, esophageal squamous cell carcinoma; NA, not available.

There were 562 CRC patients with TNM I--IV stage from included studies, but only 546 of them provided survival data.

Association Between *mSEPT9* and OS in Cancer Patients {#s3_2}
------------------------------------------------------

A total of seven studies including 786 cancer patients evaluated the association between *mSEPT9* and OS ([@B8]; [@B17]; [@B28]; [@B3]; [@B15]; [@B25]; [@B26]). The heterogeneity test showed high heterogeneity among these studies (*P~heterogeneity~* = 0.035, *I^2^* = 53.6%). The pooled HR estimated by a random-effects model was 2.07 (95% CI = 1.40--3.06), suggesting that *mSEPT9* was significantly associated with poor OS of cancer ([**Figure 2A**](#f2){ref-type="fig"}). We further explored the prognostic role of *mSEPT9* in specific subgroups ([**Table 3**](#T3){ref-type="table"}). Results revealed that patients with *mSEPT9* detected in plasma or serum suffered reduced OS than those without (HR = 3.06, 95% CI = 1.99--4.70, *P~heterogeneity~* = 0.661, *I^2^* = 0%). Particularly, *mSEPT9* detected in preoperative plasma indicated a 3.25-fold increased risk of worse survival (95% CI = 1.93--5.48, *P~heterogeneity~* = 0.489, *I^2^* = 0%). We also performed a pooled analysis to summarize data from two studies of nonmetastatic CRC (I--III) and found decreased OS in *mSEPT9*-positive patients (HR = 2.61, 95% CI = 1.47--4.65).

![Forest plots for evaluation of the association between *mSEPT9* and overall survival **(A)** or disease-free survival **(B)** in cancer patients. BTC, biliary tract carcinoma; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HNSCC, head and neck squamous cell carcinoma; MC, multiple cancers.](fgene-10-00887-g002){#f2}

###### 

Subgroup analyses of the effects of mSEPT9 on overall survival of cancer patients.

  Subgroup                                                 Number of dataset   HR (95% CI)         P~heterogeneity~   *I^2^* (%)
  -------------------------------------------------------- ------------------- ------------------- ------------------ ------------
  Plasma/Serum                                             4                   3.06 (1.99--4.70)   0.661              0
  Preoperative[^a^](#fnT3_1){ref-type="table-wrap-foot"}   3                   3.25 (1.93--5.48)   0.489              0
  CRC (I--III)[^b^](#fnT3_2){ref-type="table-wrap-foot"}   2                   2.61 (1.47--4.65)   --                 --

CRC, colorectal cancer; HR, hazard ratios; CI, confidence interval.

The sample type of the three included studies was preoperative plasma.

Because there were only two included studies focusing on overall survival of CRC, pooled HR and 95% CI were estimated, and heterogeneity was not evaluated.

Association Between *mSEPT9* and DFS in Cancer Patients {#s3_3}
-------------------------------------------------------

Two included studies comprising three datasets of 371 cancer patients reported the association of *mSEPT9*with DFS of cancer([@B18]; [@B28]). The heterogeneity test showed no heterogeneity among these studies (*P~heterogeneity~* = 0.866, *I^2^* = 0%). The pooled HR of the aforementioned studies was 3.24 (95% CI = 1.81--5.79), indicating that *mSEPT9* predicted for worse DFS in cancer patients ([**Figure 2B**](#f2){ref-type="fig"}). Subgroup analysis failed to be performed because of the limited number of relevant studies.

Association Between *mSEPT9* and DSS/PFS in Cancer Patients {#s3_4}
-----------------------------------------------------------

Only two studies reported the association of *mSEPT9* with DSS in cancer patients ([@B1]; [@B10]). Angulo et al. identified that *SEPT9* was hypermethylated in PC patients with a decreased DSS (HR = 7.64, 95% CI = 2.35--24.82) ([@B1]). However, Freitas et al. reported that *mSEPT9* independently indicated an increased DSS in CRC patients (HR = 0.67, 95% CI = 0.47--0.97), and specially, *mSEPT9* was associated with a better DSS in colon cancer (HR = 0.47, 95% CI = 0.28--0.81) ([@B10]).

For the *mSEPT9*'s prognostic role in PFS, Angulo et al. focusing on PC (HR = 2.52, 95% CI = 1.17--5.39) and Schrock et al. focusing on HNSCC (HR = 1.19, 95% CI = 1.10--1.56) both showed a significant association between *mSEPT9* and poor PFS of patients ([@B1]; [@B25]).

Sensitivity Analyses and Publication Bias {#s3_5}
-----------------------------------------

Sensitivity analyses suggested that our pooled results were quite stable for both OS ([**Supplementary Figure S1A**](#SM1){ref-type="supplementary-material"}) and DFS ([**Supplementary Figure S1B**](#SM1){ref-type="supplementary-material"}). We observed a borderline significant publication bias in meta-analysis for OS (*P~Egger's\ test~* = 0.048, *P~Begg's\ test~* = 0.063). Therefore, we conducted a trim-and-fill analysis and found that despite publication bias, the adjusted pooled HR consistently demonstrated a significant association between *mSEPT9* and OS (HR = 1.61, 95% CI = 1.09--2.38, [**Supplementary Figure S2**](#SM2){ref-type="supplementary-material"}). There was no obvious publication bias for meta-analysis for DFS (*P~Egger's\ test~* = 0.443, *P~Begg's\ test~* = 0.296).

Discussion {#s4}
==========

Several studies have investigated the association between *mSEPT9* and prognosis in human cancers, but results are uncertain due to the limited sample size and various cancer types. Herein, we conducted a systematic review and meta-analysis and supported that *mSEPT9* significantly predicted for worse cancer prognosis.

By systematic literature search, rigorous screening, and analysis, we identified that *mSEPT9*-positive cancer patients would suffer two-fold risk of decreased OS. Further subgroup analysis supported this result. Sensitivity analysis and trim-and-fill analysis guaranteed the robustness of our results. Specially, *mSEPT9* detected in preoperative plasma significantly indicated a worse OS, implying a convenient and promising way to predict long-term survival of cancer patients. In addition, our meta-analysis also supported that *mSEPT9* was significantly associated with poor DFS of cancer. Sensitivity analysis suggested that the result was stable, and Cochran's Q test and *I^2^* statistic did not indicate considerable heterogeneity. The aforementioned results all suggested that *mSEPT9* could be a good prognostic biomarker for cancer patients. Traditionally, serum tumor markers (i.e., CEA, CA19-9) are used for screening and prognosis prediction, but their performance is still unsatisfactory. Previous studies have confirmed the excellent property of *mSEPT9* in early diagnosis of several cancers and have clearly elucidated the potential mechanisms ([@B5]; [@B16]; [@B21]). Now we provide evidence to support that *mSEPT9* also could be a promising biomarker for cancer prognosis, which can be combined with traditional tumor biomarkers to greatly improve prognosis prediction in the future.

There were several limitations in our work. First, our results strongly supported that *mSEPT9* could be a prognostic indicator of OS and DFS for human cancer, but there were not enough studies for subgroup analysis to fully clarify its impact on different cancer types, sampling times, and pathological stages. Second, there were only two included studies about DSS and PFS. The limited number of studies impeded us to conduct a meta-analysis to evaluate the impact of *mSEPT9* on DSS and PFS. Last, some included studies did not provide multivariate-adjusted HRs, so we used unadjusted HRs instead. These unadjusted HRs were possibly influenced by potential confounders in the original studies. When we pooled them into a meta-analysis, the influence might be magnified and lead to a risk of bias on the pooled results. More studies with elaborate design should be conducted to verity our results and further explore more detailed impacts of *mSEPT9* on cancer prognosis.

Conclusion {#s5}
==========

Our meta-analysis suggests that *mSEPT9* could predict for worse OS and DFS in cancer patients. Specially, patients with detection of *mSEPT9* in preoperative plasma would suffer significantly decreased OS of cancer. To the best of our knowledge, this is the first meta-analysis providing robust evidence that *mSEPT9* could be a promising biomarker for cancer prognosis.
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